N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Obsessive-Compulsive Disorder (OCD) affects many children and adults, with some not responding to standard treatments.
• Glutamate dysfunction is implicated in OCD pathogenesis.
• N-acetylcysteine (NAC), a glutamate modulator, shows promise for OCD treatment in adults.

Purpose of the Study:

• To investigate the efficacy and tolerability of N-acetylcysteine (NAC) as a treatment for pediatric Obsessive-Compulsive Disorder (OCD).

Main Methods:

• A double-blind, placebo-controlled trial involving 11 children (ages 8-17) with OCD over 12 weeks.
• Participants received up to 2700 mg/day of NAC or a placebo.
• OCD symptom severity was measured using the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS).

Main Results:

• NAC treatment was associated with a significant reduction in CY-BOCS scores compared to placebo (p=0.024).
• Symptom improvement in the NAC group began around week 8.
• NAC and placebo were well-tolerated, with minimal adverse events reported in both groups.

Conclusions:

• This preliminary trial suggests N-acetylcysteine (NAC) may offer initial benefits for pediatric OCD symptom severity.
• NAC was found to be well-tolerated in children with OCD.
• Future research with larger sample sizes and multi-site designs is recommended to confirm NAC's efficacy in pediatric OCD.